Background: Protein tyrosine phosphatases are enzymes which help in the signal transduction
in diabetes, obesity, cancer, liver diseases and neurodegenerative diseases. PTP1B is the main
member of this enzyme from the protein extract of human placenta. In phosphate inhibitors development,
significant progress has been made over the last 10 years. In early-stage clinical trials, few compounds
have reached whereas in the later stage trials or registration, yet none have progressed. Many
researchers investigate different ways to improve the pharmacological properties of PTP1B inhibitors.
Objective: In the present review, authors have summarized various aspects related to the involvement of
PTP1B in various types of signal transduction mechanisms and its prominent role in various diseases
like cancer, liver diseases and diabetes mellitus.
Conclusion: There are still certain challenges for the selection of PTP1B as a drug target. Therefore,
continuous future efforts are required to explore this target for the development of PTP inhibitors to
treat the prevailing diseases associated with it.